阿尔茨海默病遗传风险、中年高血压与痴呆:ARIC神经认知研究
该研究基于ARIC前瞻性队列,纳入8931名白人和2666名黑人参与者,按种族特异性AD多基因风险评分三分位分为低、中、高遗传风险组,分析中年高血压与痴呆发病的关联。结果显示,在白人所有遗传风险组及黑人高遗传风险组中,中年高血压均与痴呆风险显著相关,但AD遗传风险并未改变高血压与痴呆的关联。数据支持所有高血压个体均可能从降压治疗中获益。
要点
- 中年高血压与痴呆风险增加相关,且不受AD遗传风险影响。
- 白人各遗传风险组及黑人高遗传风险组中,高血压均显著增加痴呆风险。
- 所有高血压患者均可能从降压治疗中获益,无论AD遗传风险高低。
核心结论
- AD遗传风险并未改变中年高血压与痴呆之间的关联。
- 数据支持所有高血压个体均可能从降压治疗中获益。
研究设计与样本
- ARIC研究为正在进行的社区前瞻性队列,涉及美国4个中心。
- 分析对象为55岁时无痴呆且具有基因型和血压数据的白人和黑人参与者。
- 基于种族特异性AD多基因风险评分三分位定义低、中、高三组遗传风险。
主要发现
- 白人参与者中,中年高血压与痴呆发病率显著相关:低风险HR 1.29(95%CI 1.07-1.55),中风险HR 1.34(95%CI 1.13-1.58),高风险HR 1.19(95%CI 1.03-1.38)。
- 黑人高遗传风险组中,中年高血压与痴呆显著相关(HR 1.31;95%CI 1.04-1.66)。
- 黑人低、中遗传风险组的关联一致但无统计学显著性。
- 高血压与痴呆的关联在不同AD遗传风险组间无显著差异。
- 高血压个体较无高血压者,80岁时痴呆概率高0%-2%,无痴呆生存概率低6%-13%。
临床怎么用
- 临床中应积极筛查和管理中年高血压,以降低痴呆风险。
- AD遗传风险评估不应作为是否进行降压治疗以预防痴呆的依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Genetics represent a nonmodifiable risk factor for Alzheimer disease (AD), with 60%-80% heritability. Midlife hypertension is a modifiable risk factor for both dementia and death. Our primary objective was to determine how genetic risk for AD modifies the association between hypertension and dementia. METHODS: The Atherosclerosis Risk in Communities Study is an ongoing community-based prospective cohort study of 4 US centers. We analyzed White and Black participants free of dementia at age 55 years with genotypes and blood pressure measured at visit 1 (1987-1989). Three genetic risk groups (low, medium, high) were defined based on tertiles of a race-specific AD polygenic risk score. Dementia was ascertained through cognitive testing, informant interviews, hospitalization, codes and death records. Death was ascertained through the National Death Index. We examined the association of midlife hypertension with incident dementia within 3 genetic risk groups using Cox proportional-hazards and cumulative incidence function estimations. We used age 55 years as the time origin, with left truncation to allow entry at ages older than 55 years; age on December 31, 2022, was the administrative censoring date. RESULTS: Among 8,931 White and 2,666 Black participants, the median follow up time was 26.6 and 23.8 years, the mean age was 54.0/53.5 years, and 53.0%/62.5% were female, respectively. After adjusting for demographics, midlife hypertension was significantly associated with dementia incidence across all genetic risk groups among White participants (low risk hazard ratio [HR] 1.29; 95% CI 1.07-1.55, medium risk HR 1.34; 95% CI 1.13-1.58, high risk HR 1.19; 95% CI 1.03-1.38) and among Black participants at high genetic risk (HR 1.31; 95% CI 1.04-1.66). Associations for low and medium genetic risk Black participants were consistent but not statistically significant. There were no significant differences in association of hypertension with dementia by AD genetic risk group. Individuals with hypertension had a 0%-2% higher probability of developing dementia by age 80 and a 6%-13% lower probability of dementia-free survival to age 80 years vs those without hypertension, across race and genetic risk groups. DISCUSSION: Genetic risk for AD does not modify the association between hypertension and dementia. These data support the fact that all individuals with hypertension are likely to benefit from antihypertensive treatment.
引用
- Morrill VN, Pike JR, Hu J, et al. Genetic Risk for Alzheimer Disease, Midlife Hypertension, and Dementia: The ARIC Neurocognitive Study. Neurology. 2026. PMID: 42385118. doi:10.1212/WNL.0000000000218280
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。